Latest Information Update: 19 Oct 2000
At a glance
- Originator Teijin Pharma
- Mechanism of Action Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Acute lung injury
Most Recent Events
- 19 Oct 2000 Discontinued-Preclinical for Acute lung injury in Japan (Unknown route)
- 14 Sep 1999 New profile
- 14 Sep 1999 Preclinical development for Acute lung injury in Japan (Unknown route)